Le Lézard
Classified in: Health
Subject: CCA

Ionis Pharmaceuticals to present at upcoming investor conferences


CARLSBAD, Calif., Nov. 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

ABOUT IONIS PHARMACEUTICALS, INC.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

SOURCE Ionis Pharmaceuticals, Inc.


These press releases may also interest you

at 12:10
The "Encephalitis Vaccines Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The Encephalitis Vaccines market is projected to grow with a CAGR of 5.2% over the forecast period. The...

at 12:02
Medicure Inc. ("Medicure" or the "Company") , a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020. The second quarter financial statements will be made available on...

at 12:01
Blue Cross Blue Shield of Massachusetts ("Blue Cross") announced today that it will return $101 million in premium refunds and anticipated rebates to its customers and members as a result of lower than anticipated health care costs during the...

at 12:00
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 117,792 cases of COVID-19 in Canada, including 8,958 deaths. 87% of people have now recovered....

at 12:00
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, along with Myocardial Solutions, a medical technology company working to transform the cardiac and cancer care continuum, announced today FDA premarket clearance...

at 12:00
Reflecting their commitment to offer the most state-of-the -art technologies to their patients, Daniel Shapiro, MD,FACS, Paradise Valley Skin Klinic in Scottsdale and Zaina Rashid, DO,FAOCD,FAAD, La Peau Dermatology in Mesa, are excited to be the...



News published on 12 november 2019 at 07:05 and distributed by: